Although pivotal clinical trials for CGRP mAbs reported low incidences of hypertension, real-world pharmacovigilance data and post-marketing surveillance reports have begun to document cases of new-onset hypertension or exacerbation of pre-existing hypertension in patients receiving these agents, particularly erenumab. The gene discussed is CALCA; the disease is hypertensive disorder.